ClinicalTrials.gg
RecruitingNCT06613568Updated Nov 19, 2026

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

An interventional study of Moda-flx Hemodialysis System™ in End Stage Kidney Disease, sponsored by Diality Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Diality Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 19, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
309th of 638
50 · median 48
Started
2025
with 18 others
No phase
287 of 765
28 open now
Primary completion
2027-03
later than 32 of 95 live
Registered
730th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 309th largest by planned enrollment of the 638 interventional ones that give a count, is one of 19 that started in 2025, is one of 287 with no phase, reaches primary completion later than 32 of the 95 other live ones, and was the 730th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

03

Conditions studied

  • End Stage Kidney Disease

Keywords

  • Renal Disease
  • Hemodialysis Complication
  • Kidney Diseases
  • Dialysis
  • Renal Dialysis
  • Hemodialysis, Home
  • Renal Insufficiency
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.
  • Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period
  • Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening
  • Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.

Exclusion criteria

Exclusion Criteria:

  • level of \< 9 g/dL at Screening
  • Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:

    1. Persistent pre-dialysis sitting SBP \< 100 mmHg despite medical therapy,
    2. Nadir intradialytic Systolic Blood Pressure (SBP) \< 90 mmHg, if Subject's pre-HD SBP \< 160 mmHg
    3. Nadir intradialytic SBP \< 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg
  • Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study
  • Participant had an average ultrafiltration rate > 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records.
  • Had a significant cardiovascular adverse event within the last 90 days prior to Screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Professional Care and At Home

    Participants will receive dialysis therapy using the Moda-Flx Hemodialysis System™ in a Professional Care setting and At Home setting

    Device: Moda-flx Hemodialysis System™

Interventions

  • DeviceModa-flx Hemodialysis System™

    The Moda-flx Hemodialysis System™ is a portable hemodialysis system

06

What researchers measure

Primary outcomes

  1. Weekly Standardized Dialysis Adequacy

    Standardized weekly (stdKt/V) values as measured once every week during the Professional Care and At Home treatment settings

    Time frame: Up to 10 weeks per period

  2. Adverse Event (AE) Rate

    The adverse event (AE) rate: defined as the number of Study Emergent AEs per 100 dialysis treatments occurring in the At Home period of the study, compared with those occurring during the Professional Care period.

    Time frame: Up to 10 weeks per period

Secondary outcomes

  1. Goal Ultrafiltration Volume

    Compliance with fluid removal goals that are defined as: Ultrafiltration (net fluid removal), such that the recorded value from the Moda-flx Hemodialysis System™ is within ± 100 mL/h or ± 250 mL (whichever is less) of set point during the treatment, based on the UF prescription.

    Time frame: Up to 10 weeks per period

  2. Study Emergent Pre-Specified Adverse Events

    Study Emergent Pre-Specified Adverse Eventss, categorized by study period (Professional Care and At Home) severity, device relationship and procedure relationship. Study-emergent Pre-Specified AEs are those AEs with an onset on or after the date of first treatment during the Run-In Period, which will be comprised of any of the following: 1\. A composite of: * Serious Adverse Event * Allergic Reaction * Blood Loss * Hemolytic Reaction * Infection * Intradialytic Event * Vascular Access Complication * Pyrogenic Reaction

    Time frame: Up to 10 weeks per period

07

Study locations

6 of 6 sites recruiting
  • North America Research Institute
    San Dimas, California 91773, United States
    Recruiting
  • New York Kidney Hypertension Medicine
    New Hyde Park, New York 11040, United States
    Recruiting
  • Nephrology Associates of Knoxville
    Knoxville, Tennessee 37920, United States
    Recruiting
  • aQua Research Institute, LLC
    Houston, Texas 77058, United States
    Recruiting
    • Ivan Ramirez · Contactivan@aqua-ri.com · 281-939-6516
    • Justin Merszei · Principal investigator
  • aQua Research Institute, LLC
    Stafford, Texas 77477, United States
    Recruiting
    • Ivan Ramirez · Contactivan@aqua-ri.com · 281-939-6516
    • Namrata Goel, MD · Principal investigator
  • University of Washington
    Seattle, Washington 98104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's planned 17 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
Oct 6, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • aQua Research Institute, LLC · Stafford, United States
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • aQua Research Institute, LLC · Houston, United StatesContact r•••@aqua-ri.com · •••6516→i•••@aqua-ri.com · •••6516Contact added (no phone or email listed)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added
    Show site
    • aQua Research Institute, LLC · Stafford, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • aQua Research Institute, LLC · Houston, United StatesContact r•••@aqua-ri.com · •••6516→i•••@aqua-ri.com · •••6516Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06613568
Lead sponsor
Diality Inc.
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Oct 6, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Michael Gastauer
Contact
HomeTrial@Diality.com
949-916-5851
Cynthia Silva, MD
study director · Diality Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion